

# Publications for Ian Marschner

## 2019

Jayawardana, K., Mundra, P., Giles, C., Barlow, C., Nestel, P., Barnes, E., Kirby, A., Thompson, P., Sullivan, D., Alshehry, Z., Marschner, I., Simes, R., et al (2019). Changes in plasma lipids predict pravastatin efficacy in secondary prevention. *JCI Insight*, 4(13), e128438. <a href="http://dx.doi.org/10.1172/jci.insight.128438">[More Information]</a>

## 2018

McKinnon, R., Cook, M., Liauw, W., Marabani, M., Marschner, I., Packer, N., Prins, J. (2018). Biosimilarity and Interchangeability: Principles and Evidence: A Systematic Review. *Biodrugs*, 32(1), 27-52. <a href="http://dx.doi.org/10.1007/s40259-017-0256-z">[More Information]</a>

Ritchie, G., Gasper, H., Man, J., Lord, S., Marschner, I., Friedlander, M., Lee, C. (2018). Defining the most appropriate primary end point in phase 2 trials of immune checkpoint inhibitors for advanced solid cancers a systematic review and meta-analysis. *JAMA Oncology*, 4(4), 522-528. <a href="http://dx.doi.org/10.1001/jamaoncol.2017.5236">[More Information]</a>

Donoghoe, M., Marschner, I. (2018). Logbin: An R package for relative risk regression using the log-binomial model. *Journal of Statistical Software*, 86, 1-22. <a href="http://dx.doi.org/10.18637/jss.v086.i09">[More Information]</a>

Sjoquist, K., Lord, S., Friedlander, M., Simes, R., Marschner, I., Lee, C. (2018). Progression-free survival as a surrogate endpoint for overall survival in modern ovarian cancer trials: a meta-analysis. *Therapeutic Advances in Medical Oncology*, 10, 1-16. <a href="http://dx.doi.org/10.1177/1758835918788500">[More Information]</a>

Stenson, B., Donoghoe, M., Brocklehurst, P., Davis, P., Juszczak, E., Marschner, I., Simes, R., Tarnow-Mordi, W. (2018). Pulse Oximeter Saturation Targeting and Oximeter Changes in the Benefits of Oxygen Saturation Targeting (BOOST)-II Australia and BOOST-II UK Oxygen Trials. *The Journal of Pediatrics*, 204, 301-304.e2. <a href="http://dx.doi.org/10.1016/j.jpeds.2018.08.033">[More Information]</a>

Lee, C., Lord, S., Marschner, I., Wu, Y., Sequist, L., Rosell, R., Fukuoka, M., Mitsudomi, T., Asher, R., Davies, L., GebSKI, V., et al (2018). The Value of Early Depth of Response in Predicting Long-Term Outcome in EGFR-Mutant Lung Cancer. *Journal of Thoracic Oncology*, 13(6), 792-800. <a href="http://dx.doi.org/10.1016/j.jtho.2018.03.010">[More Information]</a>

## 2017

Schou, I., Marschner, I. (2017). Design of clinical trials involving multiple hypothesis tests with a common control. *Biometrical Journal*, 59(4), 636-657. <a href="http://dx.doi.org/10.1002/bimj.201500230">[More Information]</a>

Lee, C., Davies, L., Wu, Y., Mitsudomi, T., Inoue, A., Rosell, R., Zhou, C., Nakagawa, K., Thongprasert, S., Fukuoka, M.,

Lord, S., Marschner, I., GebSKI, V., et al (2017). Gefitinib or erlotinib vs chemotherapy for EGFR mutation-positive lung cancer: individual patient data meta-analysis of overall survival. *Journal of the National Cancer Institute*, 109(6), 1-13. <a href="http://dx.doi.org/10.1093/jnci/djw279">[More Information]</a>

## 2016

Donoghoe, M., Marschner, I. (2016). Estimation of adjusted rate differences using additive negative binomial regression. *Statistics in Medicine*, 35(18), 3166-3178. <a href="http://dx.doi.org/10.1002/sim.6960">[More Information]</a>

Lee, C., Davies, L., GebSKI, V., Lord, S., Di Leo, A., Johnston, S., Geyer, C., Cameron, D., Press, M., Ellis, C., Marschner, I., Simes, R., et al (2016). Serum human epidermal growth factor 2 extracellular domain as a predictive biomarker for lapatinib treatment efficacy in patients with advanced breast cancer. *Journal of Clinical Oncology*, 34(9), 936-944. <a href="http://dx.doi.org/10.1200/JCO.2015.62.4767">[More Information]</a>

## 2015

Donoghoe, M., Marschner, I. (2015). Flexible regression models for rate differences, risk differences and relative risks. *The International Journal of Biostatistics*, 11(1), 91-108. <a href="http://dx.doi.org/10.1515/ijb-2014-0044">[More Information]</a>

Marschner, I. (2015). Letter to the editor. *Biostatistics*, 16(1), 1-2. <a href="http://dx.doi.org/10.1093/biostatistics/kxu025">[More Information]</a>

Schou, I., Marschner, I. (2015). Methods for exploring treatment effect heterogeneity in subgroup analysis: An application to global clinical trials. *Pharmaceutical Statistics: the journal of applied statistics in the pharmaceutical industry*, 14(1), 44-55. <a href="http://dx.doi.org/10.1002/pst.1656">[More Information]</a>

## 2014

Donoghoe, M., Marschner, I. (2014). Stable computational methods for additive binomial models with application to adjusted risk differences. *Computational Statistics and Data Analysis*, 80, 184-196. <a href="http://dx.doi.org/10.1016/j.csda.2014.06.019">[More Information]</a>

## 2013

White, H., Simes, R., Stewart, R., Blankenberg, S., Barnes, E., Marschner, I., Thompson, P., West, M., Zeller, T., Colquhoun, D., Keech, A., Sullivan, D., et al (2013). Changes in lipoprotein-associated phospholipase A2 activity predict coronary events and partly account for the treatment effect of pravastatin: results from the Long-Term Intervention with Pravastatin in Ischemic Disease study. *Journal of the American Heart Association*, 2(5), 1-12. <a href="http://dx.doi.org/10.1161/JAHA.113.000360">[More Information]</a>

Schou, I., Marschner, I. (2013). Meta-analysis of clinical trials with early stopping: an investigation of potential bias. *Statistics in Medicine*, 32(28), 4859-4874. <a href="http://dx.doi.org/10.1002/sim.5893">[More Information]</a>

## 2012

Lee, C., Marschner, I., Simes, R., Voysey, M., Egleston, B., Hudes, G., de Souza, P. (2012). Increase in Cholesterol Predicts Survival Advantage in Renal Cell Carcinoma Patients Treated with Temsirolimus. *Clinical Cancer Research*, 18(11), 3188-3196. <a href="http://dx.doi.org/10.1158/1078-0432.CCR-11-3137">[More Information]</a>

Marschner, I., Gillet, A. (2012). Relative risk regression: reliable and flexible methods for log-binomial models. *Biostatistics*, 13(1), 179-192. <a href="http://dx.doi.org/10.1093/biostatistics/kxr030">[More Information]</a>

Marschner, I., Gillet, A., O'Connell, R. (2012). Stratified additive Poisson models: Computational methods and applications in clinical epidemiology. *Computational Statistics and Data Analysis*, 56(5), 1115-1130. <a href="http://dx.doi.org/10.1016/j.csda.2011.08.002">[More Information]</a>

## 2010

Delahoy, P., Thompson, S., Marschner, I. (2010). Pregabalin versus gabapentin in partial epilepsy: a meta-analysis of dose-response relationships. *BMC Neurology*, 10, 1-11. <a href="http://dx.doi.org/10.1186/1471-2377-10-104">[More Information]</a>

Marschner, I. (2010). Regional differences in multinational clinical trials: anticipating chance variation. *Clinical Trials*, 7(2), 147-156. <a href="http://dx.doi.org/10.1177/1740774510361974">[More Information]</a>

Cui, J., Forbes, A., Kirby, A., Marschner, I., Simes, R., Hunt, D., West, M., Tonkin, A. (2010). Semi-parametric risk prediction models for recurrent cardiovascular events in the LIPID study. *BMC Medical Research Methodology*, 10(27), 1-27-9. <a href="http://dx.doi.org/10.1186/1471-2288-10-27">[More Information]</a>

Simes, R., O'Connell, R., Aylward, P., Varshavsky, S., Diaz, R., Wilcox, R., Armstrong, P., Granger, C., French, J., Van de Werf, F., Marschner, I., et al (2010). Unexplained international differences in clinical outcomes after acute myocardial infarction and fibrinolytic therapy: Lessons from the Hirulog and Early Reperfusion or Occlusion (HERO)-2 trial. *American Heart Journal*, 159(6), 988-997. <a href="http://dx.doi.org/10.1016/j.ahj.2009.12.044">[More Information]</a>

## 2008

Cui, J., Forbes, A., Kirby, A., Marschner, I., Simes, R., West, M., Tonkin, A. (2008). Parametric conditional frailty models for recurrent cardiovascular events in the lipid study. *Clinical Trials*, 5(6), 565-574. <a href="http://dx.doi.org/10.1177/1740774508098464">[More Information]</a>

## 2007

Marschner, I., Simes, R., Keech, A. (2007). Biases in the Identification of Risk Factor Thresholds and J-Curves. *American Journal of Epidemiology*, 166(7), 824-831. <a href="http://dx.doi.org/10.1093/aje/kwm145">[More Information]</a>

Keech, A., GebSKI, V., Marschner, I. (2007). Specifying objectives and outcomes for clinical trials. In Anthony Keech, Val GebSKI, Rhana Pike (Eds.), *Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials*, (pp. 21-26). Sydney: AMPCo.

## 2004

Colquhoun, D., Keech, A., Hunt, D., Marschner, I., Simes, R., Glasziou, P., White, H., Barter, P., Tonkin, A. (2004). Effects Of Pravastatin On Coronary Events In 2073 Patients With Low Levels Of Both Low-Density Lipoprotein Cholesterol And High-Density Lipoprotein Cholesterol: Results From The Lipid Study. *European Heart Journal*, 25(9), 771-777. <a href="http://dx.doi.org/10.1016/j.ehj.2004.03.013">[More Information]</a>

Marschner, I., Emberson, J., Irwig, L., Walter, S. (2004). The Number Needed To Treat (Nnt) Can Be Adjusted For Bias When The Outcome Is Measured With Error. *Journal of Clinical Epidemiology*, 57(12), 1244-1242. <a href="http://dx.doi.org/10.1016/j.jclinepi.2004.01.021">[More Information]</a>

## 2002

Jull, G., Trott, P., Potter, H., Zito, G., Niere, K., Shirley, D., Emberson, J., Marschner, I., Richardson, C. (2002). A Randomized Controlled Trial of Exercise and Manipulative Therapy for Cervicogenic Headache. *Spine*, 27(17), 1835-1843. <a href="http://dx.doi.org/10.1097/00007632-20020910-00004">[More Information]</a>

Galbraith, S., Marschner, I. (2002). Guidelines for the design of clinical trials with longitudinal outcomes. *Contemporary Clinical Trials*, 23(3), 257-273. <a href="http://dx.doi.org/10.1016/S0197-2456(02)00205-2">[More Information]</a>

Simes, R., Marschner, I., Hunt, D., Sullivan, D., Colquhoun, D., Hague, W., Stewart, R., Keech, A., Thompson, P., White, H., et al (2002). Relationship between lipid levels and clinical outcomes in the long-term intervention with pravastatin in ischemic disease (LIPID) trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels? *Circulation*, 105(10), 1162-1169. <a href="http://dx.doi.org/10.1161/hc1002.105136">[More Information]</a>

GebSKI, V., Marschner, I., Keech, A. (2002). Specifying objectives and outcomes for clinical trials. *Medical Journal of Australia*, 176(10), 491-492.

## 2001

Marschner, I., Becker, N. (2001). Advances in medical statistics arising from the AIDS epidemic. *Statistical Methods in Medical Research*, 10, 117-140.

Marschner, I., Becker, S. (2001). Interim monitoring of clinical trials based on long-term binary endpoints. *Statistics in Medicine*, 20, 177-192.

Marschner, I., Simes, R., Colquhoun, D., Glasziou, P., Harris, P., Singh, B., Friedlander, D., White, H., Thompson, P., Tonkin, A. (2001). Long-term risk stratification for survivors of acute coronary syndromes. *Journal of the American College of Cardiology*, 38(1), 56-63. <a href="http://dx.doi.org/10.1016/S0735-1097(01)01360-2">[More Information]</a>

Marschner, I. (2001). On stochastic versions of the EM algorithm. *Biometrika*, 88(1), 281-286.